Enfermedad nodular tiroidea

  1. E. Anda 1
  2. J. Pineda 1
  3. M. Toni 2
  4. J.C. Galofré 3
  1. 1 Complejo Hospitalario de Navarra. Pamplona. Navarra. España
  2. 2 Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona. Navarra. España
  3. 3 Universidad de Navarra. Pamplona. Navarra. España
Mostrar afiliaciones +
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2016

Título del ejemplar: Enfermedades endocrinológicas y metabólicas (I) Patología del tiroides

Serie: 12

Número: 13

Páginas: 713-721

Tipo: Artículo

DOI: 10.1016/J.MED.2016.06.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Introducción La patología nodular tiroidea es muy frecuente y, en la mayoría de los casos (más del 85%), se trata de nódulos benignos. Manifestaciones clínicas La mayor parte de los pacientes con enfermedad nodular tiroidea están asintomáticos. El objetivo principal del estudio del nódulo tiroideo es descartar o diagnosticar malignidad, sin olvidarnos de la función tiroidea y de la posibilidad de compresión de estructuras cervicales vecinas. Diagnóstico La historia clínica, la determinación de TSH y la ecografía cervical son los estudios iniciales que hay que realizar en todos los pacientes. La ecografía tiroidea es el mejor método de imagen para estudiar esta patología, porque además de los datos anatómicos nos proporciona características que se asocian con el riesgo de malignidad. Esto, junto con el tamaño de los nódulos, nos permitirá seleccionar aquellos en los que está indicado el estudio citológico. La citología es el método de elección para diagnosticar el nódulo tiroideo. También se pueden realizar estudios moleculares para ayudar al diagnóstico. Tratamiento Según el resultado citológico, el paciente será remitido a cirugía o únicamente vigilado sin necesidad de tratamiento; si el estudio no es concluyente deberemos repetir la punción.

Referencias bibliográficas

  • Gharib H, Papini E, Paschke R, Duick KS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologist, Associ-azione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and man-agement of thyroid nodules. Endocr Pract. 2010;16Suppl1:1-43.
  • Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high preva-lence of thyroid nodules detected by high frequency (13 MHz) ultra-sound examination. Eur J Clin Invest. 2009;39:226-31.
  • Mortensen JK, Woolner LB, Bennett WA. Gross and microscopic fin-dings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1995;15:1270-80.
  • Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med. 1995;155:2418-23.
  • Knobel M. Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. J Endocrinol Invest. 2016;39(4):357-73.
  • Bayer Y, Neumann S, Meyer B, Rüschendorf F, Reske A, Brix T, et al. Ge-nome-wide linkage analysis reveals evidence for four new susceptibility foci for familial euthyroid goiter. J Clin Endocr Metab. 2004;89:4044-53.
  • Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutzky I, Weinstein R, Lazar L, et al. Clinical characteristics and outcome of fami-lial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21:43-8.
  • Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endo-crinol Metabol. 2012;26:83-96.
  • Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-Fluorodeoxyglucose Positron Emission Tomography: a systematic review. Thyroid. 2012;22:918-25.
  • Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Ci-bas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411-7.
  • Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Pre-valence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23:449-55.
  • Alexander K, Hurwitz S, Heering B, Benson CB, Frates MC, Doubilet PM, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med. 2003;138:315-8.
  • Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, et al. The natural history of benign thyroid nodules. JAMA. 2015;313: 926-35.
  • Ajmal S, Rapoport S, Ramírez H, Mazzaglia PJ. The natural history of the benign thyroid nodule: What is the appropriate follow-up strategy? J Am Coll Surg. 2015;220:987-92.
  • Vivanco, M, Dalle JH, Alberti C, Lescoeur B, Yakouben K, Carel JC, et al. Malignant and benign thyroid nodules after total body irradiation pre-ceding hematopoietic cell transplantation during childhood. Eur J Endo-crinol. 2012;167:225-33.
  • Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, et al. A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst. 2006;13:897-903.
  • Rowland KJ, Moley JF. Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol. 2015;111:51-60.
  • Rutter M, Jha P, Schultz KA, Sheil A, Harris A, Bauer, et al. DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct as-sociation. J Clin Endocrinol Metab. 2016;101:1-5.
  • Son EJ, Nosé V. Familial follicular cell-derived thyroid carcinoma. Front Endocrinol (Lausanne). 2012;3:61.
  • Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295-301.
  • Haymart MR, Repplinger KJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-14.
  • Cooper DS, Doherty GM, Haugen BT, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
  • Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94:1748-51.
  • Haugen BR, Alexander EK, Bible KC Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association manage-ment guidelines for adult patients with thyroid nodules and diffe-rentiated thyroid cancer. Thyroid. 2016;26:1-133.
  • Kovács G, Gonda G, Vadász G, Ludmány E, Uhrin K, Görömbey Z, et al. Epidemiology of thyroid microcarcinoma found in autopsy series con-ducted in areas of different iodine intake. Thyroid. 2005;2:152-7.
  • Ito Y, Miyauchi A, Inoue H. An observational trial for papillary thyroid microcarcinoma in Japanese patients. Worl J Surg. 2010;34:28-35.
  • Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopatho-logy. Am J Clin Pathol. 2009;132:658-65.
  • Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for reporting thyroid cytopathology: a meta-analysis. Acta Cytologica. 2012;56:333-9.
  • Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98:1852-60.
  • Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indetermi-nate cytology. N Engl J Med. 2012;367:705-15.
  • Yoo WS, Choi HS, Cho SW, Moon JH, Kim KW, Park HJ, et al. The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. Clin Endocrinol. 2014; 80:735-42.
  • Kwak JY, Koo H, Youk JH, Kim MJ, Moon HJ, Son EJ, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Ra-diology. 2010;254:292-300.
  • Nou E, Kwsong N, Alexanter LD, Cibas ES, Marqusee E, Alexander EK. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab. 2014;99: 510-16.
  • Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME, et al. Thyroid nodules (≥4 cm): can ultrasound and cytology reliable exclude cancer? World J Surg. 2014;38:614-21.
  • Albuja-Cruz MB, Goldfarb M, Gondek SS, Allan BJ, Lew JL. Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. J Surg Res. 2013;181:6-10.
  • Sdano MT, Falciglia M, Welge JA, Steward DL. Efficacy of thyroid hor-mone suppression for benign thyroid nodules: meta-analysis of randomi-zed trials. Otolaryngol Head Neck Surg. 2005;133:391.
  • Suh CH, Baek JH, Ha EJ, Choi YJ, Lee JH, Kim JK, et al. Ethanol abla-tion of predominantly cystic thyroid nodules: evaluation of recurrence rate and factors related to recurrence. Clin Radiol. 2015;70:42-7.
  • Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radio-frequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol. 2008;18:1244-39.
Fuente de los datos: Dialnet